Completed PHASE3 INTERVENTIONAL 2-arm NCT00645671

Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

A Randomized Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery

Sponsor: Bausch & Lomb Incorporated

Conditions Ocular Inflammation

Interventions 0.5% Loteprednol Etabonate Ophthalmic Ointment Vehicle of Loteprednol Etabonate Ophthalmic Ointment

Updated 6 times since 2017 Last updated: Mar 4, 2015 Started: Mar 31, 2008 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00645671, this PHASE3 trial focuses on Ocular Inflammation and remains completed. Sponsored by Bausch & Lomb Incorporated, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch & Lomb Incorporated

Data source: Bausch & Lomb Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States